Company news
Dimerix Limited (ASX:DXB) news
Dimerix Limited news releases on 6ix. Latest, Aug 29, 2024: Preliminary Final Report
Press releases — page 2
Preliminary Final Report
August 28, 2024
Adolescent Recruitment into ACTION3 Clinical Trial
July 3, 2024
Dimerix and Taiba enter into License Agreement for DMX-200
May 26, 2024
Dimerix Receives PIP Approval from the UK MHRA
April 30, 2024
Dimerix Completes $20M Placement
March 11, 2024
Dimerix Successfully Passes Efficacy Interim Analysis
March 10, 2024
PH3 Data Collection Complete for First Interim Analysis
February 26, 2024
Half-Year Financial Report & Appendix 4D - 31 December 2023
February 25, 2024
ACTION3 IND Approved in China
November 27, 2023
Dimerix Receives Initial Upfront Payment from Advanz Pharma
November 5, 2023
Dimerix Announces License Agreement for EU, Canada, ANZ
October 4, 2023
FDA Approves Qytovra Brand Name
September 24, 2023
Regulatory Approval received in Malaysia for ACTION3 Study
September 21, 2023
Dimerix Receives $8.9M R&D Tax Incentive Rebate
September 12, 2023
Successful Completion of 2nd DSMB Review of FSGS Trial
August 7, 2023
DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24
July 23, 2023
Approval received for Paediatric Investigation Plan from EMA
July 4, 2023
Dimerix confirms Phase 3 study design appropriate for China
July 2, 2023
Prospectus
June 26, 2023
Dimerix Announces Update on Successful Capital Raise
June 5, 2023
Rights Issue Prospectus
May 4, 2023
Reinstatement to Official Quotation
May 3, 2023
Entitlement offer and Convertible Note to raise $12 million
May 3, 2023
Voluntary Suspension
May 2, 2023
Half-Year Financial Report & Appendix 4D - 31 December 2022
February 26, 2023
DXB to Receive $2.8m in Prepayment of R&D Tax Incentive
February 16, 2023
Successful Completion of DSMB Review of Phase 3 FSGS Trial
February 8, 2023
FDA Confirms Inclusion of Paediatrics in ACTION3 Study
January 11, 2023
DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved
December 14, 2022
CLARITY 2.0 COVID-19 Study Outcome
December 12, 2022
Chair address and CEO presentation to AGM
November 28, 2022
Dimerix Receives A$6.0M R&D Tax Incentive Rebate
October 24, 2022
Appendix 4E and 2022 Annual Report
August 28, 2022
CLARITY 2.0 COVID-19 Study Concludes Recruitment
August 17, 2022
New Patent Family Application for DMX-700
August 8, 2022
DMX-700 Study Shows Significant 80% Reduction in Lung Injury
July 3, 2022
REMAP-CAP COVID-19 Study Analysis Update
June 26, 2022
New Clinical Trial for DMX-200 in Diabetic Kidney Disease
June 6, 2022
Phase 3 FSGS Kidney Trial First Patient Recruited
May 30, 2022
Dimerix presentation at Bioshares Biotech Summit
May 11, 2022
FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
May 8, 2022
Dimerix Receives A$3.7M R&D Tax Incentive Rebate
March 28, 2022
DSMB Change to REMAP-CAP COVID-19 Study
February 27, 2022
Half-Year Financial Report & Appendix 4D - 31 December 2021
February 23, 2022
First Regulatory Approval in Europe for DMX-200 FSGS Study
February 1, 2022
Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
January 10, 2022
Ethics Approval in Australia for Phase 3 COVID-19 Study
December 22, 2021
DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe
December 16, 2021
Pause in Trading
December 15, 2021
First Approvals Received for Start of Phase 3 FSGS Trial
October 20, 2021